Cargando…

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER2 oncogene alterations

Human epidermal growth factor receptor 2 (HER2) is a member of the HER family of proteins containing four receptor tyrosine kinases. It plays an important role in the pathogenesis of certain human cancers. In non‐small‐cell lung cancer (NSCLC), HER2 amplification or mutations have been reported. How...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzawa, Ken, Toyooka, Shinichi, Sakaguchi, Masakiyo, Morita, Mizuki, Yamamoto, Hiromasa, Tomida, Shuta, Ohtsuka, Tomoaki, Watanabe, Mototsugu, Hashida, Shinsuke, Maki, Yuho, Soh, Junichi, Asano, Hiroaki, Tsukuda, Kazunori, Miyoshi, Shinichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724821/ https://www.ncbi.nlm.nih.gov/pubmed/26545934 http://dx.doi.org/10.1111/cas.12845

Ejemplares similares

Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib
por: Hashida, Shinsuke, et al.
Publicado: (2015)

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018)

Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features
por: Sato, Hiroki, et al.
Publicado: (2017)

Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway
por: Ohtsuka, Tomoaki, et al.
Publicado: (2016)

Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations
por: Ogoshi, Yusuke, et al.
Publicado: (2019)

Primary pulmonary melanoma: a report of two cases
por: Watanabe, Mototsugu, et al.
Publicado: (2015)

Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas
por: Yamamoto, Hiromasa, et al.
Publicado: (2013)

Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer
por: Takeda, Tatsuaki, et al.
Publicado: (2017)

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
por: Sato, Hiroki, et al.
Publicado: (2018)

Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells
por: Yoshioka, Takahiro, et al.
Publicado: (2019)

Anti-Cancer Effects of REIC/Dkk-3-encoding Adenoviral Vector for the Treatment of Non-small Cell Lung Cancer
por: Shien, Kazuhiko, et al.
Publicado: (2014)

TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells
por: Otani, Hiroki, et al.
Publicado: (2015)

DNA methylation status of REIC/Dkk-3 gene in human malignancies
por: Hayashi, Tatsuro, et al.
Publicado: (2012)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis
por: Takahashi, Yuta, et al.
Publicado: (2018)

DV200 Index for Assessing RNA Integrity in Next-Generation Sequencing
por: Matsubara, Takehiro, et al.
Publicado: (2020)

The proliferative effects of asbestos-exposed peripheral blood mononuclear cells on mesothelial cells
por: MAKI, YUHO, et al.
Publicado: (2016)

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer
por: Sato, Hiroki, et al.
Publicado: (2018)

Identification of genetic loci associated with renal dysfunction after lung transplantation using an ethnic-specific single-nucleotide polymorphism array
por: Tomioka, Yasuaki, et al.
Publicado: (2023)

Author Correction: Identification of genetic loci associated with renal dysfunction after lung transplantation using an ethnic-specific single-nucleotide polymorphism array
por: Tomioka, Yasuaki, et al.
Publicado: (2023)

One-step nucleic acid amplification for intraoperative diagnosis of lymph node metastasis in lung cancer patients: a single-center prospective study
por: Namba, Kei, et al.
Publicado: (2022)

YES1 activation induces acquired resistance to neratinib in HER2‐amplified breast and lung cancers
por: Takeda, Tatsuaki, et al.
Publicado: (2020)

Donor-derived cell-free DNA is associated with acute rejection and decreased oxygenation in primary graft dysfunction after living donor-lobar lung transplantation
por: Tanaka, Shin, et al.
Publicado: (2018)

Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma
por: Namba, Kei, et al.
Publicado: (2019)

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Masuda, Tomomi, et al.
Publicado: (2020)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

Functional Blockage of S100A8/A9 Ameliorates Ischemia–Reperfusion Injury in the Lung
por: Nakata, Kentaro, et al.
Publicado: (2022)

Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer‐associated fibroblast
por: Ochi, Kosuke, et al.
Publicado: (2022)

Robot-assisted thoracoscopic lobectomy for severe incomplete interlober fissure
por: Okazaki, Mikio, et al.
Publicado: (2021)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
por: Kato, Yuka, et al.
Publicado: (2018)

EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery
por: Fujiwara, Toshiya, et al.
Publicado: (2023)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
por: Chen, Dong, et al.
Publicado: (2020)

Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody
por: Tomioka, Yasuaki, et al.
Publicado: (2021)

Surgical outcome of ipsilateral anatomical resection for lung cancer after pulmonary lobectomy
por: Okazaki, Mikio, et al.
Publicado: (2023)

Durable response to afatinib rechallenge in a long‐term survivor of non‐small cell lung cancer harboring EGFR L858R and L747V mutations
por: Kanbe, Mio, et al.
Publicado: (2022)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
por: Chen, Yi-Chieh, et al.
Publicado: (2021)

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
por: Fang, Yueh‐Fu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_orodveqa2vq8gsu532v3ioa5vp